slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 226,021-226,050
Pages 10,126
Rows per page 30
Component
226,021-226,050 of 303,780
30
The table shows adjustments for share-based compensation and depreciation & amortization to arrive at non-IFRS metrics.Freightos | Investor Presentation Deck | 34 slides · Freightos
Pitch deck Investor relations 1 hit
31
Freightos | Investor Presentation Deck | 34 slidesFreightos | Investor Presentation Deck | 34 slides · Freightos
Pitch deck Investor relations 1 hit
32
The table shows adjustments for share-based compensation and depreciation & amortization.Freightos | Investor Presentation Deck | 34 slides · Freightos
Pitch deck Investor relations 1 hit
33
Freightos | Investor Presentation Deck | 34 slidesFreightos | Investor Presentation Deck | 34 slides · Freightos
Pitch deck Investor relations 1 hit
34
Freightos | Investor Presentation Deck | 34 slidesFreightos | Investor Presentation Deck | 34 slides · Freightos
Pitch deck Investor relations 1 hit
01
Freyr | Results Presentation Deck | 14 slidesFreyr | Results Presentation Deck | 14 slides · FREYR
Conference presentation Investor relations 1 hit
04
The slide title mentions 4 key messages, but only 2 are presented on this page.Freyr | Results Presentation Deck | 14 slides · FREYR
Conference presentation Investor relations Beat · Problem1 hit
05
Freyr | Results Presentation Deck | 14 slidesFreyr | Results Presentation Deck | 14 slides · FREYR
Conference presentation Investor relations Beat · Problem1 hit
06
Freyr | Results Presentation Deck | 14 slidesFreyr | Results Presentation Deck | 14 slides · FREYR
Conference presentation Investor relations Beat · Solution1 hit
01
Fusion Pharmaceuticals | Investor Presentation Deck | 30 slidesFusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
02
Fusion Pharmaceuticals | Investor Presentation Deck | 30 slidesFusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
04
The slide uses a linear process flow to highlight competitive differentiation.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · ProblemLoop · Why Now1 hit
05
The slide uses a Gantt-style visualization to represent drug development stages.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · ProblemLoop · Why Now1 hit
06
The slide emphasizes vertical integration and strategic supply agreements as a moat.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
07
Includes a logo grid of previous affiliations at the bottom.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
08
Fusion Pharmaceuticals | Investor Presentation Deck | 30 slidesFusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
09
Includes a visual case study (Subject #4) showing PET scan response.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
10
Includes a clinical case study image showing patient response to therapy.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · Market Opportunity1 hit
12
The slide outlines a standard clinical trial dose escalation design (3+3) for a radiopharmaceutical.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · Market Opportunity1 hit
13
Fusion Pharmaceuticals | Investor Presentation Deck | 30 slidesFusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
16
The slide uses a process flow diagram to map out different study arms and their respective patient cohorts.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
17
The chart shows FPI-1434 Plasma AUC for two different dosing regimens.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
18
The slide highlights a specific program (Program 1) involving dual targeting of EGFR and cMET using Fusion's FastClear linker technology.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
19
The slide uses a combination of a process diagram for the in vivo study and a line chart to show efficacy results.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
20
Fusion Pharmaceuticals | Investor Presentation Deck | 30 slidesFusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
21
The slide combines financial status with a timeline of clinical milestones.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
22
Fusion Pharmaceuticals | Investor Presentation Deck | 30 slidesFusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
23
Fusion Pharmaceuticals | Investor Presentation Deck | 30 slidesFusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
24
The slide uses medical imaging (SPECT/CT) to visually demonstrate the efficacy of a pre-dose strategy in optimizing pharmacokinetics.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
25
The slide presents clinical trial data comparing pharmacokinetics and safety (thrombocytopenia) profiles.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit